69 351

Cited 0 times in

Two cases of primary CNS lymphoma treated with rituximab and temozolomide

Other Title
원발성 중추신경계 림프종에서 리툭시맵과 테모졸로미드 병합치료
Authors
이, 윤석; 김, 무정; 이, 현우; 박, 준성; 조, 경기; 김, 효철
Citation
The Korean journal of medicine, 75(suppl.3):S806-S810, 2008
Journal Title
The Korean journal of medicine; 대한내과학회지
ISSN
1738-93642289-0769
Abstract
저자들은 두통, 기억력 감퇴, 시야결손의 증상을 주소로 내원한 환자에서 두경부 MRI를 시행하여 원발성 중추신경계 림프종을 의심하였고, 뇌정위적 생검을 시행하여 확진한 후 rituximab과 temozolomide로 병합치료 후 특이 부작용 없이 완전관해에 도달하였기에 문헌고찰과 함께 보고하는 바이다.

Primary CNS lymphoma (PCNSL) is rare, occurring in 2~3% of all non-Hodgkin’s lymphoma. However, in recent years the incidence has increased. To date, the main treatment modalities are radiation therapy, steroids, methotrexate, or combination therapies. The response and overall prognosis remain poor. Use of CHOP in PCNSL has been disappointing in overall response, presumably due to poor penetration through the blood-brain barrier (BBB). We experienced excellent results using a combination of rituximab and the BBB-penetrating alkylating agent temozolomide. Two cases were diagnosed with PCNSL (diffuse large B cell lymphoma) with strong CD 20 positivity. They were placed on a 3-week cycle of rituximab 375 mg/m2 and 5 days of temozolomide 150 mg/m2. After six cycles of chemotherapy, repeat MRIs showed complete remission. Overall, tolerance to chemotherapy was excellent, with no significant marrow suppression. The combination of rituximab and temozolomide may be an effective regimen for the treatment of primary CNS lymphoma.
Keywords
원발성 중추신경계 림프종리툭시맵테모졸로미드Primary central nervous system lymphomaRituximabTemozolomide
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Neurosurgery
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
이, 현우박, 준성조, 경기김, 효철
Files in This Item:
fulltext not available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse